Skip to main content

6Node page

what any key link opens

psx:substance/ethylmorphine/section/pharmacokinetic-detail.full@1

sectionreferenced by edges — no row of its own

derived from · upstream

feeds · downstream

none recorded

Closure of psx:substance/ethylmorphine/section/pharmacokinetic-detail.full@1: 31 upstream, 40 downstream.

psx:substance/ethylmorphine/section/pharmacokinetic-detail.full@1
├─ informed_by  claim/d8c5c465-812b-4e16-8a91-d7ecbecf9023  Claim in pharmacokinetic-detail — partially_supported
├─ informed_by  claim/8c9920dd-f7f8-4b3e-ad2e-21e776ee94aa  Claim in pharmacokinetic-detail — supported
├─ informed_by  claim/39820684-5164-4340-8255-b4509f345501  Claim in pharmacokinetic-detail — supported
├─ informed_by  claim/83f764fc-8686-455e-8abd-b7a8bb51273d  Claim in pharmacokinetic-detail — supported
├─ informed_by  claim/b5c4a5ce-334a-4685-a3e5-c4708b8c22ae  Claim in pharmacokinetic-detail — supported
├─ informed_by  claim/f2817af0-bb3b-4863-9f7d-7bbcf040e26a  Claim in pharmacokinetic-detail — supported
├─ informed_by  claim/90e87012-6dfc-4e35-8006-4a9ba02fba10  Claim in pharmacokinetic-detail — partially_supported
├─ informed_by  claim/f81dac23-04df-4f06-b336-316252859218  Claim in pharmacokinetic-detail — inconclusive  working
  ├─ used  src/pmid:9547411  Morphine formation from ethylmorphine: implications for drugs-of-abuse testing in urine
  ├─ used  src/pmid:18430293  Driving under the influence of opiates: concentration relationships between morphine, codeine, 6-acetyl morphine, and ethyl morphine in blood
  ├─ used  src/pmid:7654478  Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose
  ├─ used  src/doi:10.1208/s12249-020-01759-0  Core in Cup Ethylmorphine Hydrochloride Tablet for Dual Fast and Sustained Pain Relief: Formulation, Characterization, and Pharmacokinetic Study
  ├─ used  src/pmid:9421105  Urinary excretion of codeine, ethylmorphine, and their metabolites: relation to the CYP2D6 activity
      ├─ used  src/url:d5a2df930261de7f  Ethylmorphine
      ├─ used  src/pmid:8024470  Ethylmorphine concentrations in human samples in an overdose case
      ├─ used  src/pmid:9140136  Effects of ethanol on ethylmorphine metabolism in isolated rat hepatocytes: characterization by means of a multicompartmental model
      ├─ used  src/url:26736bb7725f6b5a  Ethylmorphine - Wikidoc
      ├─ used  src/doi:10.4236/ajac.2012.312a115  Supercritical Fluid Chromatography—Mass Spectrometry (SFC-MS) and MALDI-TOF-MS of Heterocyclic Compounds with Trivalent and Pentavalent Nitrogen in Cough Relief Medical Forms Tuxi and Cosylan
      ├─ used  src/url:0f6a4957844947f7  Ethylmorphine — PubChem Compound CID 5359271
      ├─ used  src/doi:10.1002/jnr.23059  Inhibition by morphine and its analogs of action potentials in adult rat dorsal root ganglion neurons
      ├─ used  src/doi:10.1016/j.lfs.2008.06.002  Inhibitory effects of opioids on compound action potentials in frog sciatic nerves and their chemical structures
      ├─ used  src/pmid:9747665  Adverse effects of opioid agonists and agonist-antagonists in anaesthesia.
      ├─ used  src/pmid:27042732  'Weak' opioid analgesics. Codeine, dihydrocodeine and tramadol: no less risky than morphine
      ├─ used  src/pmid:9574808  Ethylmorphine N-demethylase activity as a marker for cytochrome P450 CYP3A activity in rat hepatic microsomes
      ├─ used  src/pmid:2471291  Depression of hepatic glutathione by opioid analgesic drugs in mice
      ├─ used  src/doi:10.2174/1570159X13666141210215423
      ├─ used  src/pmid:11111800  Lethal combination of tramadol and multiple drugs affecting serotonin
      ├─ used  src/doi:10.1007/s40265-021-01515-z  Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles
      ├─ derived_from  gen/36330135-74f9-4e34-93ca-73ed5dbd517c  Generation — pipeline-v5
      ├─ generated_by  pub/45db9626-f645-424f-a883-e1118640803d  Publication — backfill
      └─ invalidated_by  pub/91e0b471-8517-4e1a-9e5e-10c0b8fffce5  Publication — publish
    ├─ used  version/1  Revision 1
    ├─ used  claim/5e85862f-d30f-4678-95aa-e8e0e2601ab0  Claim in legal-status — supported
    ├─ used  claim/3ee5bd40-1409-4978-b061-622444bf96f8  Claim in legal-status — supported
    ├─ used  claim/0faa2dfc-851f-4550-8a74-aba92a7737c4  Claim in clinical-evidence — supported
    ├─ used  claim/7e4c0b8a-76b6-452b-986b-2d35cd3a2f0e  Claim in summary — not_supported  working
    ├─ used  claim/9eff90d5-631b-4906-8d22-428a8ba8e20a  Claim in history — supported
    ├─ used  claim/9eee5a3c-6272-4715-9461-20b43cda1eb6  Claim in clinical-evidence — supported
    ├─ used  claim/39d5adb2-a185-4560-9fa5-1fa791243a30  Claim in safety — supported
    ├─ used  claim/5268f943-25c1-4684-9ee1-80c76686e46c  Claim in safety — supported
    ├─ used  claim/5142d385-abbd-4481-9882-3f72c737ed45  Claim in safety — supported
    ├─ used  claim/b0259f22-3915-48c5-a61c-92df111f7bfb  Claim in safety — supported
    ├─ used  claim/b281fbf8-55e7-42a4-8571-a49af91d4ac8  Claim in history — supported
    ├─ used  claim/f853cc06-e1e1-4fa4-8a55-0b314f31d6be  Claim in summary — supported
    ├─ used  claim/8af160ca-63bf-4700-88ba-4ed46845be3f  Claim in history — inconclusive  working
    ├─ used  claim/10f1ff07-0ec5-427f-9e19-285470b793b3  Claim in pharmacology — supported
    ├─ used  claim/9deca80c-4f1d-480b-ba36-7f3e2ba71e39  Claim in pharmacology — inconclusive  working
    ├─ used  claim/894629e1-3851-4e2a-924e-9689b7c33ab7  Claim in pharmacology — supported
    ├─ used  claim/5a877a25-4b01-4d35-b76b-1953ed23c1db  Claim in pharmacology — supported
    ├─ used  claim/1b2c5b9e-fc55-4da3-a43f-c4058a7e670b  Claim in pharmacology — supported
    ├─ used  claim/12c2b644-707f-4097-8717-d90d6a6ddfc2  Claim in safety — supported
    ├─ used  claim/fdb2f322-ab77-41f3-9b15-813c969b5633  Claim in clinical-evidence — supported
    ├─ used  claim/b5ad27b6-f0b2-40f1-8bce-f3b417d99ecb  Claim in pharmacology — supported
    ├─ used  claim/38ea185e-cfea-4c1f-bc9a-47e49cfe00c3  Claim in clinical-evidence — supported
    ├─ used  claim/579d80d0-4078-4ef1-afe4-6a7825a381f0  Claim in summary — partially_supported
    ├─ used  claim/21067eeb-8dca-4134-bf0e-54ccde36495d  Claim in pharmacology — supported
    ├─ used  claim/41af2e04-4b0d-4b4f-8103-eb1c765b519a  Claim in pharmacology — inconclusive  working
    ├─ used  claim/dc8715f4-5049-400d-9d10-b7a617b21ac2  Claim in pharmacology — supported
    ├─ used  claim/6dad2542-0bab-468d-b7a9-caef4f7cf911  Claim in clinical-evidence — supported
    ├─ used  claim/1432842c-5625-4cd7-9159-3c001330ce84  Claim in comparative-pharmacology — supported
      ├─ derived_from  issue/notice@0cf53f8ee191  Issued notice
      ├─ derived_from  issue/info_card@4a78db9b8d0f  Issued info_card
      ├─ derived_from  issue/emergency@f85b2d2362c9  Issued emergency
      ├─ revised_from  version/2  r1.a1
      ├─ informed_by  section/legal-status.full@1
      ├─ informed_by  section/clinical-evidence.full@1
      ├─ informed_by  section/summary.full@1
      ├─ informed_by  section/history.full@1
      ├─ informed_by  section/safety.full@1
      ├─ informed_by  section/pharmacology.full@1
      └─ informed_by  section/comparative-pharmacology.full@1
… closure truncated at 200 nodes

indented by distance from this node, not by parentage

1Provenance card

the boundary, as counts

Sources

206 with DOI

1 strong · 15 moderate · 4 weak

Compilations

42026-05-10T19:58:01.613Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

35last ruled 2026-10-02

0 awaiting a ruling

Issued documents

42026-10-02T13:08:33.667Z

notice · info card · emergency

Searches

191 with no results

queries and counts on the build

Claims checked

9471 supported

71 supported · 23 not

Correspondence

0received

consent field ships in Phase 4

Edges

279

derivations recorded for this entity

Complete over 20 sources, 4 compilations, and 35 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/ethylmorphine/archive

2Build

one panel per compilation run

generation run 2026-05-09

47 min failedmodel not recordedplan not recordedrun/dde0556f…

research

no artifact

draft

no artifact

audit

no artifact

verify

no artifact

simplify

no artifact

publish

no artifact

Selection

results seen0
selected by the model0
consumed as sources20

Verification

claims checked0
supported0
partially supported0
not supported0
inconclusive0
  • record
  • seen / partial
  • working

The model's own caveats

none raised on this run

Reproduce

inputs
20 source keys (listed under Sources)
plan
not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model
not recorded
streams
none — agent transcripts are persisted from 2026-09 onward

generation run 2026-05-10

0 min failedmodel not recordedplan not recordedrun/a9d24927…

research

no artifact

draft

no artifact

audit

no artifact

verify

no artifact

simplify

no artifact

publish

no artifact

Selection

results seen0
selected by the model0
consumed as sources20

Verification

claims checked0
supported0
partially supported0
not supported0
inconclusive0
  • record
  • seen / partial
  • working

The model's own caveats

none raised on this run

Reproduce

inputs
20 source keys (listed under Sources)
plan
not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model
not recorded
streams
none — agent transcripts are persisted from 2026-09 onward

generation run 2026-05-10

0 min failedmodel not recordedplan not recordedrun/d634ce3b…

research

no artifact

draft

no artifact

audit

no artifact

verify

no artifact

simplify

no artifact

publish

no artifact

Selection

results seen0
selected by the model0
consumed as sources20

Verification

claims checked0
supported0
partially supported0
not supported0
inconclusive0
  • record
  • seen / partial
  • working

The model's own caveats

none raised on this run

Reproduce

inputs
20 source keys (listed under Sources)
plan
not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model
not recorded
streams
none — agent transcripts are persisted from 2026-09 onward

generation run 2026-05-10

74 min completedmodel pipeline-v5plan not recordedrun/d36b37b2…

Selection

results seen79
selected by the model31
consumed as sources20

Verification

claims checked94
supported62
partially supported9
not supported1
inconclusive22
  • record
  • seen / partial
  • working

The model's own caveats

  • sparse_evidence
  • structural_inference

Reproduce

inputs
20 source keys (listed under Sources)
plan
not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model
pipeline-v5
streams
none — agent transcripts are persisted from 2026-09 onward
19 searches — query, source, results, what was kept and why
19 searches for this run
#sourcequeryseenkeptrationale
1PubMedethylmorphine drug driving impairment forensic11Forensic and blood concentration data
2PubMedethylmorphine pharmacology opioid receptor44All directly relevant to ethylmorphine pharmacology
3ClinicalTrials.gov · absenceethylmorphine00No active or completed trials identified
4PubChemethylmorphine11Primary chemical identity source
5PubMedmorphine formation from ethylmorphine implications drugs-of-abuse testing11Key metabolic and forensic data
6PubMedethylmorphine codeine morphine urinary excretion opiate testing11Directly relevant to ethylmorphine metabolism and CYP2D6 role
7PubMedethylmorphine pharmacokinetics metabolism102—
8HandWikiethylmorphine pharmacology11Comprehensive multi-jurisdiction legal and chemical data
9OpenAlexethylmorphine antitussive cough analgesic clinical102Confirms Cosylan product and antitussive class context
10PubChemCID 535927111Verified chemical identity
11Webethylmorphine Cosylan Norway ophthalmic dionine historical medical use103Historical and clinical use data
12Webethylmorphine dionine legal status scheduling US DEA UK international102Key legal status data
13PubMedtramadol opioid interaction serotonin syndrome seizure pharmacodynamic52Opioid combination interaction data with mechanistic detail
14Web/Handwikiethylmorphine SMILES CAS physical properties13Physical/chemical identity data missing from PubChem API response
15PubMedethylmorphine pharmacokinetics biotransformation Cosylan11Definitive human PK study for ethylmorphine - most important single pharmacokinetics reference
16Webethylmorphine Australia scheduled poison101Legal status in Australia
17PubMedethylmorphine overdose death concentration11Only published fatal case - critical safety-critical reference
18Webethylmorphine half life pharmacokinetics elimination103Located critical references via web search supplementing PubMed results
19PubMedethylmorphine ethanol metabolism interaction11Mechanistic basis for the lethal ethylmorphine-alcohol interaction
94 claims by section — every cited sentence, checked against its source
safety25 · 20 ok
  • The only published fatal overdose documents a femoral blood ethylmorphine concentration of 488 ng/mL at autopsysupported

    Fatal overdose case attributed to oral ethylmorphine ingestion. Femoral blood concentration 488 ng/mL. pmid:8024470

  • For context, the mean blood concentration in impaired drivers was 55 ng/mL (median 30 ng/mL), placing the fatal concentration at approximately 9 times the mean therapeutic and impaired-driving blood levelsupported

    Ethylmorphine found in 63/2573 impaired driver blood samples in Sweden. Mean concentration 0.055 mg/L (median 0.03 mg/L). pmid:18430293

  • Hair analysis revealed a pattern of heroin use followed by a switch to ethylmorphine abuse.supported

    Hair analysis showed switching from heroin to ethylmorphine. pmid:8024470

  • Claim in safety — inconclusiveinconclusiveworking →

  • The risk is dose-dependent and markedly potentiated by concurrent CNS depressants.supported

    synergistic interactions with hypnosedatives on sedation, breathing and blood pressure. pmid:9747665

  • Ethylmorphine, along with morphine, hydromorphone, and LAAM, significantly depletes hepatic glutathione (GSH) in ICR mice when administered intraperitoneally, with the effect mediated centrally via mu-opioid receptor stimulationsupported

    Morphine, hydromorphone, ethylmorphine, LAAM, and meperidine all caused significant decrease in hepatic GSH in ICR mice. Ethylmorphine active via central (icv) route suggesting CNS-mediated mechanism via mu-opioid receptor. pmid:2471291

  • Claim in safety — inconclusiveinconclusiveworking →

  • Cognitive impairment: Mu-opioid agonists produce dose-dependent impairment of attention, psychomotor speed, and executive function. Impaired-driving data from Sweden (63 of 2,573 samples positive for ethylmorphine) confirm psychomotor impairment at therapeutic and supratherapeutic concentrations.supported

    Ethylmorphine found in 63/2573 impaired driver blood samples in Sweden. Mean concentration 0.055 mg/L (median 0.03 mg/L). pmid:18430293

  • Claim in safety — inconclusiveinconclusiveworking →

  • The drug elimination half-life (2 hours) is distinct from the tolerance persistence half-life — these represent fundamentally different phenomena and should not be conflated.supported

    t1/2 2 h. pmid:7654478

  • Claim in safety — inconclusiveinconclusiveworking →

  • Ethylmorphine carries significant dependence liability, documented by forensic evidence of abuse: switching from heroin to ethylmorphine, use as an intoxicant in impaired driving, and classification as a controlled substance across major jurisdictionssupported

    Hair analysis showed switching from heroin to ethylmorphine. pmid:8024470

  • Ethylmorphine carries significant dependence liability, documented by forensic evidence of abuse: switching from heroin to ethylmorphine, use as an intoxicant in impaired driving, and classification as a controlled substance across major jurisdictionssupported

    Ethylmorphine found in 63/2573 impaired driver blood samples in Sweden. pmid:18430293

  • The most critical interaction involves alcohol (ethanol), which inhibits all three metabolic pathways of ethylmorphine in a concentration-dependent manner: O-deethylation reduced 44%, N-demethylation reduced 35%, and glucuronidation reduced 30–60% at physiologically relevant ethanol concentrations (100 mM)supported

    At 100mM ethanol: total elimination reduced 38%, N-demethylation to norethylmorphine reduced 35%, O-deethylation to morphine reduced 44%, glucuronidation most affected (30-60% reduction). pmid:9140136

  • Total elimination rate decreases by 38%supported

    total elimination reduced 38%. pmid:9140136

  • GHB at plasma concentrations of approximately 500 mg/L can independently cause death via cardiorespiratory collapse; GBL converts to GHB within approximately 1 minute of ingestionsupported

    GBL/BD → GHB (t1/2~1 min). Plasma ~100 mg/L euphoria, 500 mg/L potentially fatal via cardiorespiratory depression. 1570159x13666141210215423

  • GHB at plasma concentrations of approximately 500 mg/L can independently cause death via cardiorespiratory collapse; GBL converts to GHB within approximately 1 minute of ingestionsupported

    GBL/BD → GHB (t1/2~1 min). Plasma ~100 mg/L euphoria, 500 mg/L potentially fatal via cardiorespiratory depression. 1570159x13666141210215423

  • Tramadol additionally lowers seizure threshold and carries serotonin syndrome risk in polypharmacy contexts.supported

    Seizure threshold lowered by tramadol; risk enhanced by concurrent serotonergic drugs. pmid:11111800

  • Tramadol additionally lowers seizure threshold and carries serotonin syndrome risk in polypharmacy contexts.supported

    tramadol likely more serotonergic AEs (nausea, vomiting). s40265-021-01515-z

  • Tramadol additionally lowers seizure threshold and carries serotonin syndrome risk in polypharmacy contexts.supported

    Seizure threshold lowered by tramadol; risk enhanced by concurrent serotonergic drugs. First reported death from seizure in a tramadol patient on serotonergic drugs. pmid:11111800

  • Claim in safety — inconclusiveinconclusiveworking →

  • Concurrent CNS depressant use (absolute): Co-administration with alcohol, benzodiazepines, barbiturates, GHB/GBL, or other opioids is contraindicated due to additive respiratory depression risk.supported

    Ethanol inhibits all metabolic steps of ethylmorphine... total elimination reduced 38%. pmid:9140136

  • CYP2D6 ultrarapid metabolizer status (relative): Ultrarapid metabolizers are at elevated risk of morphine toxicity from standard therapeutic doses — a relative contraindication established by analogy with codeine pharmacogenomic safety data .supported

    CYP2D6 polymorphism influences potency. All weak opioids share same dose-dependent adverse effects as morphine including respiratory depression and addiction. pmid:27042732

  • Hepatic impairment (relative): Given the extensive first-pass hepatic metabolism and the hepatic glutathione depletion documented in animal models, pre-existing hepatic impairment may alter both the efficacy (reduced morphine formation) and the toxicity profile of ethylmorphine.supported

    Morphine, hydromorphone, ethylmorphine, LAAM, and meperidine all caused significant decrease in hepatic GSH in ICR mice. pmid:2471291

  • Impaired driving and machinery operation: Psychomotor impairment is documented at therapeutic and supratherapeutic concentrations.supported

    Ethylmorphine found in 63/2573 impaired driver blood samples in Sweden. Mean concentration 0.055 mg/L (median 0.03 mg/L). pmid:18430293

pharmacology21 · 14 ok
  • Its pharmacological activity is largely mediated by the metabolite morphine, formed through hepatic CYP2D6-catalyzed O-deethylation, rather than by direct mu-receptor binding of the parent compound.supported

    CYP2D6 polymorphism affects morphine formation (9-fold individual variation). pmid:7654478

  • Its pharmacological activity is largely mediated by the metabolite morphine, formed through hepatic CYP2D6-catalyzed O-deethylation, rather than by direct mu-receptor binding of the parent compound.supported

    CYP2D6 EM excreted more morphine than PM after ethylmorphine 25 mg oral (11.0% vs 3.0% of dose, p<0.05). pmid:9421105

  • In rat brain homogenate ³H-DAMGO displacement assays, increasing alkyl chain length at the 3-O position progressively reduces mu-receptor binding affinity, with the potency order: morphine (Ki = 1.2 nM) > codeine > ethylmorphine > pholcodinepartially supported

    Binding affinity to mu receptor of opioids chemically related to morphine and metabolites examined in rat brain homogenates with 3H-DAMGO. Decreasing length of alkyl group at position 3 decreased Ki values (morphine < codeine < ethylmorphine < pholcodine). pmid:1851921

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Independently of opioid receptor activity, ethylmorphine inhibits compound action potentials in peripheral nerve fibers through a non-opioid, naloxone-insensitive mechanism consistent with local anesthetic-like membrane partitioningsupported

    Ethylmorphine (IC50 0.70 mM) was more potent than codeine or morphine at inhibiting action potentials in rat DRG neurons via non-opioid-receptor mechanism (naloxone-resistant). jnr.23059

  • Independently of opioid receptor activity, ethylmorphine inhibits compound action potentials in peripheral nerve fibers through a non-opioid, naloxone-insensitive mechanism consistent with local anesthetic-like membrane partitioningsupported

    Ethylmorphine IC50 4.6 mM for CAP reduction in frog sciatic nerve; potency order ethylmorphine > codeine > dihydrocodeine >= morphine; effect naloxone-resistant and related to chemical structure. j.lfs.2008.06.002

  • In adult rat dorsal root ganglion neurons, ethylmorphine showed IC₅₀ = 0.70 mM for action potential inhibition — more potent than codeine (IC₅₀ = 2.5 mM) or morphine (IC₅₀ = 2.9 mM)partially supported

    Ethylmorphine (IC50 0.70 mM) was more potent than codeine or morphine at inhibiting action potentials in rat DRG neurons via non-opioid-receptor mechanism (naloxone-resistant). Potency sequence: ethylmorphine > codeine = morphine. jnr.23059

  • In frog sciatic nerve preparations, IC₅₀ = 4.6 mM, again exceeding the potency of codeine and morphinesupported

    Ethylmorphine IC50 4.6 mM for CAP reduction in frog sciatic nerve; potency order ethylmorphine > codeine > dihydrocodeine >= morphine. j.lfs.2008.06.002

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • (3) Direct glucuronidation → ethylmorphine-6-glucuronide — the major urinary metabolitesupported

    Major metabolite: ethylmorphine-6-glucuronide. pmid:7654478

  • Ethylmorphine N-demethylase (EMD) activity serves as a validated marker for CYP3A activity in rat liver microsomes, responding to classic CYP3A inducers (pregnenolone-16α-carbonitrile, dexamethasone, phenobarbital)supported

    EMD (ethylmorphine N-demethylase) evaluated as CYP3A marker. PCN, DEX and PB induced EMD ~3-13-fold. EMD selectivity for CYP3A confirmed by inhibition with anti-CYP3A1 antibodies and TAO. pmid:9574808

  • In male rats, the rat-specific CYP2C11 isoform also contributes to constitutive EMD activity.supported

    Constitutive CYP3A and CYP2C11 both contribute to EMD in male rats. pmid:9574808

  • Human pharmacokinetic parameters from a single oral dose of Cosylan cough syrup (N = 10 healthy subjects) showed median Tmax of 45 minutes and terminal elimination half-life of 2 hours, with 77% urinary recovery of ethylmorphine and measured metabolites over 48 hourssupported

    PK study in 10 healthy subjects using Cosylan. Median tmax 45 min, t1/2 2 h. Urinary recovery 77% over 48h. pmid:7654478

  • Inter-individual variation in morphine formation was 9-fold, not fully explained by CYP2D6 genotype alone.supported

    CYP2D6 polymorphism affects morphine formation (9-fold individual variation). Two subjects phenotypically classified as CYP2D6 poor metabolizers. pmid:7654478

  • A formulation pharmacokinetic study using a commercial oral tablet reported Tmax of 2.20 ± 0.24 hours and Cmax of 172.05 ± 12.53 ng/mLsupported

    vs. market tablet Cpmax 172.05 ng/mL at 2.20 h. s12249-020-01759-0

  • CYP2D6 poor metabolizers form significantly less morphine (3% vs. 11% of dose in extensive metabolizers, p < 0.05), though ethylmorphine produces proportionally more morphine than an equivalent dose of codeine regardless of phenotype (7.0% vs. 3.8%, p < 0.05).supported

    CYP2D6 EM excreted more morphine than PM after ethylmorphine 25 mg oral (11.0% vs 3.0% of dose, p<0.05). More morphine formed from ethylmorphine than codeine regardless of phenotype (7.0% vs 3.8%). pmid:9421105

clinical-evidence9 · 9 ok
  • Forensic toxicology reports documenting blood concentrations in impaired drivers and a fatal overdose casesupported

    Ethylmorphine found in 63/2573 impaired driver blood samples in Sweden. Mean concentration 0.055 mg/L (median 0.03 mg/L). pmid:18430293

  • Forensic toxicology reports documenting blood concentrations in impaired drivers and a fatal overdose casesupported

    Fatal overdose case attributed to oral ethylmorphine ingestion. Femoral blood concentration 488 ng/mL. pmid:8024470

  • Pharmacokinetic studies characterizing absorption, metabolism, and excretion in healthy volunteerssupported

    PK study in 10 healthy subjects using Cosylan. Median tmax 45 min, t1/2 2 h. Urinary recovery 77% over 48h. pmid:7654478

  • Pharmacokinetic studies characterizing absorption, metabolism, and excretion in healthy volunteerssupported

    Urinary excretion of codeine, ethylmorphine, and their metabolites: relation to the CYP2D6 activity. pmid:9421105

  • Pharmacokinetic studies characterizing absorption, metabolism, and excretion in healthy volunteerssupported

    Urinary excretion: 42-47% recovered over 48h. Morphine/EtM ratio >1 by 12-24h interval. pmid:9547411

  • CYP450 metabolism studies in animal modelssupported

    EMD (ethylmorphine N-demethylase) evaluated as CYP3A marker. PCN, DEX and PB induced EMD ~3-13-fold. pmid:9574808

  • Formulation studies evaluating novel drug delivery systemssupported

    Formulation study of dual-release ethylmorphine HCl tablets. s12249-020-01759-0

  • In vitro pharmacology characterizing receptor binding and nerve conduction effectssupported

    Binding affinity to mu receptor of opioids chemically related to morphine and metabolites examined in rat brain homogenates with 3H-DAMGO. pmid:1851921

  • In vitro pharmacology characterizing receptor binding and nerve conduction effectssupported

    Ethylmorphine IC50 4.6 mM for CAP reduction in frog sciatic nerve. j.lfs.2008.06.002

pharmacokinetic-detail8 · 7 ok
  • The morphine-to-ethylmorphine urinary ratio increases over time following a single oral dose, exceeding 1.0 at 12–24 hours post-dose and rising above 10 at late time points (N = 10, doses 25 and 50 mg)partially supported

    Urinary excretion: 42-47% recovered over 48h. Morphine/EtM ratio >1 by 12-24h interval. EMIT screening positive 100% in first 24h for both doses. pmid:9547411

  • Analysis of 2,573 impaired driver blood samples from Sweden identified ethylmorphine in 63 samples (2.4%), with a mean concentration of 0.055 mg/L (55 ng/mL) and median of 0.03 mg/L (30 ng/mL)supported

    Ethylmorphine found in 63/2573 impaired driver blood samples in Sweden. Mean concentration 0.055 mg/L (median 0.03 mg/L). pmid:18430293

  • Data from Aasmundstad et al. and ElMeshad et al..supported

    PK study in 10 healthy subjects using Cosylan. Median tmax 45 min, t1/2 2 h. Urinary recovery 77% over 48h. pmid:7654478

  • Data from Aasmundstad et al. and ElMeshad et al..supported

    Formulation study of dual-release ethylmorphine HCl tablets. In vivo absorption data: Cpmax 354.12 ng/mL attained after 3.0 h (vs. market tablet Cpmax 172.05 ng/mL at 2.20 h). s12249-020-01759-0

  • CYP2D6 phenotype significantly alters the metabolic fate of ethylmorphine:supported

    CYP2D6 EM excreted more morphine than PM after ethylmorphine 25 mg oral (11.0% vs 3.0% of dose, p<0.05). pmid:9421105

  • Regardless of CYP2D6 phenotype, ethylmorphine produces proportionally more morphine than codeine (7.0% vs. 3.8%, p < 0.05)supported

    More morphine formed from ethylmorphine than codeine regardless of phenotype (7.0% vs 3.8%). pmid:9421105

  • EMIT opiate immunoassay screens were positive in 100% of subjects during the first 24 hours at both dose levels, and remained positive in ≥67% of subjects at 24–48 hours.partially supported

    EMIT screening positive 100% in first 24h for both doses. pmid:9547411

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

summary7 · 6 ok
  • Ethylmorphine's opioid activity is largely mediated by its metabolite morphine, formed via hepatic CYP2D6-catalyzed O-deethylationsupported

    CYP2D6 polymorphism affects morphine formation (9-fold individual variation). pmid:7654478

  • Ethylmorphine occupies a position between codeine and morphine in clinical potency, with weaker direct mu-receptor affinity than either parent compound.partially supported

    Decreasing length of alkyl group at position 3 decreased Ki values (morphine < codeine < ethylmorphine < pholcodine). pmid:1851921

  • The parent compound exhibits substantially weaker direct mu-opioid receptor binding than either morphine or codeine, with increasing 3-O-alkyl chain length progressively reducing receptor affinitysupported

    Decreasing length of alkyl group at position 3 decreased Ki values (morphine < codeine < ethylmorphine < pholcodine). Many opioids exert pharmacological actions predominantly through metabolites. pmid:1851921

  • CYP2D6 polymorphism produces up to 9-fold inter-individual variation in morphine formation, with poor metabolizers converting approximately 3% of the dose to morphine versus 11% in extensive metabolizers.partially supported

    CYP2D6 EM excreted more morphine than PM after ethylmorphine 25 mg oral (11.0% vs 3.0% of dose, p<0.05). pmid:9421105

  • One published fatal overdose documents a femoral blood concentration of 488 ng/mL — approximately 9 times the mean therapeutic blood levelsupported

    Fatal overdose case attributed to oral ethylmorphine ingestion. Femoral blood concentration 488 ng/mL. pmid:8024470

  • Claim in summary — not_supportednot supportedworking →

  • Combination with CNS depressants produces a dual-mechanism lethal risk: pharmacokinetic inhibition of all metabolic pathways compounds pharmacodynamic respiratory depression synergismsupported

    Ethanol inhibits all metabolic steps of ethylmorphine. At 100mM ethanol: total elimination reduced 38%, N-demethylation to norethylmorphine reduced 35%, O-deethylation to morphine reduced 44%, glucuronidation most affected (30-60% reduction). pmid:9140136

receptor-pharmacology6 · 5 ok
  • Ethylmorphine inhibits neuronal action potentials through a receptor-independent mechanism insensitive to the opioid antagonist naloxonesupported

    effect naloxone-resistant and related to chemical structure. j.lfs.2008.06.002

  • Ethylmorphine inhibits neuronal action potentials through a receptor-independent mechanism insensitive to the opioid antagonist naloxonesupported

    Ethylmorphine (IC50 0.70 mM) was more potent than codeine or morphine at inhibiting action potentials in rat DRG neurons via non-opioid-receptor mechanism (naloxone-resistant). jnr.23059

  • The available data establishes relative ordering only: in rat brain homogenate ³H-DAMGO displacement assays, increasing 3-O-alkyl chain length progressively reduces mu-receptor binding affinity in the order morphine (Ki = 1.2 nM) > codeine > ethylmorphine > pholcodinepartially supported

    Decreasing length of alkyl group at position 3 decreased Ki values (morphine < codeine < ethylmorphine < pholcodine). pmid:1851921

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • The greater potency of ethylmorphine in action potential inhibition — 3.6- to 4.1-fold more potent than morphine and codeine in dorsal root ganglion neurons — reflects enhanced membrane partitioning due to the longer alkyl chainpartially supported

    Ethylmorphine (IC50 0.70 mM) was more potent than codeine or morphine at inhibiting action potentials in rat DRG neurons via non-opioid-receptor mechanism (naloxone-resistant). Potency sequence: ethylmorphine > codeine = morphine. jnr.23059

  • Both studies confirmed that this effect is naloxone-insensitive, establishing a non-opioid mechanism.supported

    non-opioid-receptor mechanism (naloxone-resistant). jnr.23059

history5 · 3 ok
  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Hair analysis in a fatal overdose case revealed a pattern of switching from heroin to ethylmorphine, and blood samples from impaired drivers in Sweden confirmed its use as an intoxicantsupported

    Hair analysis showed switching from heroin to ethylmorphine. pmid:8024470

  • Hair analysis in a fatal overdose case revealed a pattern of switching from heroin to ethylmorphine, and blood samples from impaired drivers in Sweden confirmed its use as an intoxicantsupported

    Ethylmorphine found in 63/2573 impaired driver blood samples in Sweden. Mean concentration 0.055 mg/L (median 0.03 mg/L). pmid:18430293

  • Of 2,573 impaired driver blood samples analyzed, 63 (2.4%) contained ethylmorphine.supported

    Ethylmorphine found in 63/2573 impaired driver blood samples in Sweden. pmid:18430293

neuroscience5 · 1 ok
  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Non-opioid nerve block clinical relevance: The naloxone-insensitive action potential inhibition demonstrated in vitro raises the question of whether this mechanism contributes to the clinical effects of ophthalmic ethylmorphine formulations (Dionine eye drops), which may have achieved relevant local concentrations. No published investigation has addressed this question.supported

    Ethylmorphine (IC50 0.70 mM) was more potent than codeine or morphine at inhibiting action potentials in rat DRG neurons via non-opioid-receptor mechanism (naloxone-resistant). jnr.23059

comparative-pharmacology4 · 4 ok
  • Data from Chen et al..supported

    Mu receptor binding of some commonly used opioids and their metabolites. pmid:1851921

  • Morphine yield: Ethylmorphine produces proportionally more morphine per dose than codeine (7.0% vs. 3.8% urinary excretion as morphine, p < 0.05). This suggests modestly greater opioid efficacy at equivalent milligram doses.supported

    More morphine formed from ethylmorphine than codeine regardless of phenotype (7.0% vs 3.8%). pmid:9421105

  • Direct receptor binding: Ethylmorphine has weaker direct mu-receptor binding than codeine, making it more dependent on metabolic activation for its opioid effects.supported

    Decreasing length of alkyl group at position 3 decreased Ki values (morphine < codeine < ethylmorphine < pholcodine). Many opioids exert pharmacological actions predominantly through metabolites. pmid:1851921

  • Non-opioid nerve block: Ethylmorphine is 3.6-fold more potent than codeine in inhibiting action potentials in dorsal root ganglion neurons (IC₅₀ 0.70 mM vs. 2.5 mM).partially supported

    Ethylmorphine (IC50 0.70 mM) was more potent than codeine or morphine at inhibiting action potentials in rat DRG neurons. Potency sequence: ethylmorphine > codeine = morphine. jnr.23059

chemistry2 · 0 ok
  • Claim in chemistry — inconclusiveinconclusiveworking →

  • Claim in chemistry — inconclusiveinconclusiveworking →

legal-status2 · 2 ok
  • Following ingestion, urine tests positive for morphine on standard opiate immunoassays — 100% of subjects tested positive in the first 24 hours after single oral doses of 25–50 mg, with the morphine-to-ethylmorphine ratio exceeding 1.0 by 12–24 hourssupported

    EMIT screening positive 100% in first 24h for both doses. Morphine/EtM ratio >1 by 12-24h interval. pmid:9547411

  • Following ingestion, urine tests positive for morphine on standard opiate immunoassays — 100% of subjects tested positive in the first 24 hours after single oral doses of 25–50 mg, with the morphine-to-ethylmorphine ratio exceeding 1.0 by 12–24 hourssupported

    EMIT screening positive 100% in first 24h for both doses. Morphine/EtM ratio >1 by 12-24h interval. pmid:9547411

3Sources

20 consumed · sorted by year · feeds = sections resting on it

Sources
yearsourcetierstatusfeeds
2024Ethylmorphine — PubChem Compound CID 5359271National Center for Biotechnology Informationurl:0f6a4957844947f7moderateconsumedcited only
2023Ethylmorphineurl:d5a2df930261de7fweakconsumedcited only
2022Ethylmorphine - Wikidocurl:26736bb7725f6b5aweakconsumedcited only
2021Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety ProfilesRoulet L, Rollason V, Desmeules J, Piguet V · Drugsdoi:10.1007/s40265-021-01515-zmoderateconsumed1 section
2020Core in Cup Ethylmorphine Hydrochloride Tablet for Dual Fast and Sustained Pain Relief: Formulation, Characterization, and Pharmacokinetic StudyElMeshad AN, Abdel-Haleem KM, Abdel Gawad NA, El-Nabarawi MA, Sheta NM · AAPS PharmSciTechdoi:10.1208/s12249-020-01759-0moderateconsumed3 sections
2016'Weak' opioid analgesics. Codeine, dihydrocodeine and tramadol: no less risky than morphinePrescrire International · Prescrire Internationalpmid:27042732moderateconsumed2 sections
2015GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndromeBusardò FP, Jones AW · Current Neuropharmacologydoi:10.2174/1570159x13666141210215423strongconsumedcited only
2012Inhibition by morphine and its analogs of action potentials in adult rat dorsal root ganglion neuronsMizuta K, Fujita T, Kumamoto E · Journal of Neuroscience Researchdoi:10.1002/jnr.23059moderateconsumed4 sections
2012Supercritical Fluid Chromatography—Mass Spectrometry (SFC-MS) and MALDI-TOF-MS of Heterocyclic Compounds with Trivalent and Pentavalent Nitrogen in Cough Relief Medical Forms Tuxi and CosylanBrondz I, Brondz A · American Journal of Analytical Chemistrydoi:10.4236/ajac.2012.312a115moderateconsumed2 sections
2008Driving under the influence of opiates: concentration relationships between morphine, codeine, 6-acetyl morphine, and ethyl morphine in bloodJones AW, Holmgren A, Kugelberg FC · Journal of Analytical Toxicologypmid:18430293moderateconsumed5 sections
2008Inhibitory effects of opioids on compound action potentials in frog sciatic nerves and their chemical structuresMizuta K, Fujita T, Nakatsuka T, Kumamoto E · Life Sciencesdoi:10.1016/j.lfs.2008.06.002moderateconsumed3 sections
2000Lethal combination of tramadol and multiple drugs affecting serotoninRipple MG, Pestaner JP, Levine BS, Smialek JE · American Journal of Forensic Medicine and Pathologypmid:11111800weakconsumed1 section
1998Adverse effects of opioid agonists and agonist-antagonists in anaesthesia.Bowdle TA · Drug Safetypmid:9747665moderateconsumed3 sections
1998Ethylmorphine N-demethylase activity as a marker for cytochrome P450 CYP3A activity in rat hepatic microsomesAmacher DE, Schomaker SJ · Toxicology Letterspmid:9574808moderateconsumed2 sections
1998Morphine formation from ethylmorphine: implications for drugs-of-abuse testing in urinePopa C, Beck O, Brodin K · Journal of Analytical Toxicologypmid:9547411moderateconsumed3 sections
1997Effects of ethanol on ethylmorphine metabolism in isolated rat hepatocytes: characterization by means of a multicompartmental modelXu BQ, Aasmundstad TA, Lillekjendlie B, Bjørneboe A, Christophersen AS, Mørland J · Pharmacology & Toxicologypmid:9140136moderateconsumed3 sections
1997Urinary excretion of codeine, ethylmorphine, and their metabolites: relation to the CYP2D6 activityHedenmalm K, Sundgren M, Granberg K, Spigset O, Dahlqvist R · Therapeutic Drug Monitoringpmid:9421105moderateconsumed5 sections
1995Biotransformation and pharmacokinetics of ethylmorphine after a single oral doseAasmundstad TA, Xu BQ, Johansson I, Ripel A, Bjørneboe A, Christophersen AS, Bodd E, Mørland J · British Journal of Clinical Pharmacologypmid:7654478moderateconsumed6 sections
1994Ethylmorphine concentrations in human samples in an overdose caseKintz P, Jamey C, Mangin P · Archives of Toxicologypmid:8024470weakconsumed4 sections
1989Depression of hepatic glutathione by opioid analgesic drugs in miceSkoulis NP, James RC, Harbison RD, Roberts SM · Toxicology and Applied Pharmacologypmid:2471291moderateconsumed1 section
—Searched ClinicalTrials.gov for "ethylmorphine" — no resultsabsenceno results—

4Docket

one filing per activity — decisions, correspondence, reports

  1. 0012026-05-10revisionRevision 1

    Initial LLM generation (v5 pipeline, wiki, prose phase)

    psx:substance/ethylmorphine/version/1
  2. 0022026-06-04proposal29 value proposals approved together

    one review action inferred from a shared reviewer and instant — the graph records one activity per proposal

    29 items in this filing

    • contraindication · other
    • contraindication · age
    • contraindication · other
    • contraindication · metabolic
    • contraindication · hepatic
    • contraindication · neurological
    • contraindication · other
    • dose_tier · threshold
    • dose_tier · light
    • dose_tier · common
    • dose_tier · strong
    • dose_tier · heavy
    • timeline · oral · onset
    • timeline · oral · come_up
    • timeline · oral · peak
    • timeline · oral · resolution
    • timeline · oral · afterglow
    • toxicity
    • dependence · full
    • withdrawal
    • tolerance
    • dosage · oral
    • duration · oral · onset
    • duration · oral · come_up
    • duration · oral · peak
    • duration · oral · offset
    • duration · oral · total
    • duration · oral · aftereffects
    psx:substance/ethylmorphine/proposal/contraindication/f2748ded-b295-44f1-8f6f-9240186d9a47
  3. 0032026-06-04publicationPublication — backfill
  4. 0042026-10-02rulingRuling — psx:substance/ethylmorphine/proposal/article_section_proposals/00bf7d5b-e422-4aeb-a59e-300dca31ba09founder
  5. 0052026-10-02rulingRuling — psx:substance/ethylmorphine/proposal/article_section_proposals/be2e257b-9a64-4ade-a736-0256a53a7d19founder
  6. 0062026-10-02revisionr1.a1
  7. 0072026-10-02publicationPublication — publishagent-psx

5Issued documents

what the notice, info card and emergency page said, by hash

Issued documents
documentcontent hashissuedfrom versionsuperseded
info_card96fce0d974b05737d636b0d5…2026-10-02 13:08Revision 2current
emergencyf85b2d2362c98030e2585598…2026-09-04 04:30Revision 1current
info_card4a78db9b8d0f303dfe135343…2026-09-04 04:30Revision 1superseded2026-10-02
notice0cf53f8ee1915726ee5ef1da…2026-09-04 04:30Revision 1current